EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?

Masatoshi Kudo

Liver Cancer · 05.09.2026 · 15 (5) · 649-659

DOI: 10.1159/lic/admag018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 27.10.2026. Verfasst von Masatoshi Kudo. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kudo, M. (2026). EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?. Liver Cancer, 15(5), 649-659. https://doi.org/10.1159/lic/admag018

Vancouver

Kudo M. EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?. Liver Cancer. 2026;15(5):649-659. doi:10.1159/lic/admag018

BibTeX
@article{Kudo2026,
  author = {Kudo, Masatoshi},
  title = {EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?},
  journal = {Liver Cancer},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {649--659},
  doi = {10.1159/lic/admag018}
}
Kostenlos starten →